UPDATE 1-ViroPharma ends development of hepatitis C drug
(Recasts, adds details)
April 16 (Reuters) - ViroPharma Inc (VPHM.O) said it discontinued the development of its experimental hepatitis C drug due to safety concerns.
ViroPharma, which was developing the drug, HCV-796, with Wyeth (WYE.N), said it does not expect to continue to collaborate with Wyeth on future development of hepatitis C treatment candidates.
The company said the risk associated with potential liver toxicity posed too high a hurdle to merit further development of the drug.
ViroPharma halted the mid-stage trial of HCV-796 in August 2007 after some patients developed elevated liver enzymes, a warning signal for liver damage.
ViroPharma shares, which closed at $9.62 Wednesday on Nasdaq, fell 6 percent to $9.05 in trading after the bell. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Vinu Pilakkott)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
